|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 631 |
FusionGeneSummary for ACTR3_IGHG1 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ACTR3_IGHG1 | Fusion gene ID: 631 | Hgene | Tgene | Gene symbol | ACTR3 | IGHG1 | Gene ID | 10096 | 3500 |
| Gene name | ARP3 actin related protein 3 homolog | immunoglobulin heavy constant gamma 1 (G1m marker) | |
| Synonyms | ARP3 | - | |
| Cytomap | 2q14.1 | 14q32.33 | |
| Type of gene | protein-coding | other | |
| Description | actin-related protein 3actin-like protein 3 | constant region of heavy chain of IgG1immunoglobulin gamma 1 (Gm marker) | |
| Modification date | 20180519 | 20180523 | |
| UniProtAcc | P61158 | P01857 | |
| Ensembl transtripts involved in fusion gene | ENST00000263238, ENST00000536059, ENST00000535589, | ENST00000390548, | |
| Fusion gene scores | * DoF score | 10 X 9 X 5=450 | 32 X 42 X 3=4032 |
| # samples | 10 | 46 | |
| ** MAII score | log2(10/450*10)=-2.16992500144231 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(46/4032*10)=-3.13178987255554 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: ACTR3 [Title/Abstract] AND IGHG1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | ACTR3 | GO:0034314 | Arp2/3 complex-mediated actin nucleation | 11741539 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | AW176085 | ACTR3 | chr2 | 114647889 | + | IGHG1 | chr14 | 106208463 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000263238 | ENST00000390548 | ACTR3 | chr2 | 114647889 | + | IGHG1 | chr14 | 106208463 | - |
| 5UTR-3CDS | ENST00000536059 | ENST00000390548 | ACTR3 | chr2 | 114647889 | + | IGHG1 | chr14 | 106208463 | - |
| intron-3CDS | ENST00000535589 | ENST00000390548 | ACTR3 | chr2 | 114647889 | + | IGHG1 | chr14 | 106208463 | - |
Top |
FusionProtFeatures for ACTR3_IGHG1 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ACTR3 | IGHG1 |
| Functions as ATP-binding component of the Arp2/3 complexwhich is involved in regulation of actin polymerization andtogether with an activating nucleation-promoting factor (NPF)mediates the formation of branched actin networks. Seems tocontact the pointed end of the daughter actin filament. Plays arole in ciliogenesis. {ECO:0000269|PubMed:20393563,ECO:0000269|PubMed:9000076}. | Constant region of immunoglobulin heavy chains.Immunoglobulins, also known as antibodies, are membrane-bound orsecreted glycoproteins produced by B lymphocytes. In therecognition phase of humoral immunity, the membrane-boundimmunoglobulins serve as receptors which, upon binding of aspecific antigen, trigger the clonal expansion and differentiationof B lymphocytes into immunoglobulins-secreting plasma cells.Secreted immunoglobulins mediate the effector phase of humoralimmunity, which results in the elimination of bound antigens(PubMed:22158414, PubMed:20176268). The antigen binding site isformed by the variable domain of one heavy chain, together withthat of its associated light chain. Thus, each immunoglobulin hastwo antigen binding sites with remarkable affinity for aparticular antigen. The variable domains are assembled by aprocess called V-(D)-J rearrangement and can then be subjected tosomatic hypermutations which, after exposure to antigen andselection, allow affinity maturation for a particular antigen(PubMed:17576170, PubMed:20176268). {ECO:0000303|PubMed:17576170,ECO:0000303|PubMed:20176268, ECO:0000303|PubMed:22158414}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for ACTR3_IGHG1 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for ACTR3_IGHG1 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ACTR3_IGHG1 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for ACTR3_IGHG1 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | IGHG1 | C0027121 | Myositis | 1 | CTD_human |
| Tgene | IGHG1 | C0032460 | Polycystic Ovary Syndrome | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|